REPL - Replimune shares rise 9% following positive clinical trial updates for lead candidate

Replimune (REPL) shares are up 9% after the company issued positive updates on two clinical trials of its lead candidate.The company said it was amending the phase 2 CERPASS trial examining RP1 in combination with Libtayo (cemiplimab) for non-melanoma skin cancer to include complete response rate as a primary endpoint and reducing trial enrollment to 180 from 240 patients.Replimune expects initial data in 2022.For the company's IGNYTE single-arm trial, RP1 is being combined with Opdivo (nivolumab) for anti-PD1 failed melanoma.The FDA has agreed that if data is compelling enough, it could be considered as part of a submission to the FDA under the accelerate approval pathway.Initial data from this study is also expected next year.

For further details see:

Replimune shares rise 9% following positive clinical trial updates for lead candidate